Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Breast Neoplasms × Imatinib Mesylate × Clear all

Phase

Phase 2 4 Phase 1 2 Phase NA 1 Phase 4 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Gastrointestinal Stromal Tumors 2 Progressive Gastrointestinal Stromal Tumor 1 Myeloproliferative Disorders 1 Mastocytosis, Systemic 1 Mastocytosis 1 Mast Cell Activation Disorders 1 Leukemia, Myeloid, Chronic-Phase 1 Hematologic Neoplasms 1 Breast Neoplasms 1 Blast Crisis 1

Interventions

Letrozole 20 Docetaxel 16 Cyclophosphamide 13 Zoledronic Acid 12 exemestane 11 Trastuzumab 11 Anastrozole 11 Paclitaxel 10 Tamoxifen 9 Capecitabine 9 Fulvestrant 8 Epirubicin 8 pegfilgrastim 7 pertuzumab 6 liposomal doxorubicin 6 abemaciclib 6 Saline Solution 6 palbociclib 5 Sodium Chloride 5 Dexmedetomidine 5 Carboplatin 5 Bupivacaine 5 Bevacizumab 5 ribociclib 4 pegylated granulocyte colony-stimulating factor 4 eribulin 4 Tranexamic Acid 4 Standard of Care 4 Pamidronate 4 Filgrastim 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00372476 2017-02-07

INV181

Novartis

Phase 4 Completed

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡